401 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
on impairment of intangible assets related to rostafuroxin of $6.8 million and a related $1.4 million deferred income tax benefit and a non-cash loss … related to rostafuroxin of $6.8 million and a related $1.4 million deferred income tax benefit.
The Company reported a net loss of $20.3 million ($5.24
8-K
EX-10.1
c49o8vt1
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-2.1
mu76nx 0vijcka
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-4.1
39x015k
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-3.1
p9h5m737
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-10.1
7ha vxg4tvhmda
25 Jan 24
Entry into a Material Definitive Agreement
8:34am
8-K
EX-1.1
l0rnq 38ji1
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
8-K
EX-99.1
lxvwr8 m9lwofmb8qsl
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
424B5
au9zg fzxf3y
9 Nov 23
Prospectus supplement for primary offering
4:11pm